COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. Richard Schneiderman

Dr. Richard Schneiderman

Scientific Review Officer


Division of Translational and Clinical Sciences DTCS
Cardiovascular and Respiratory Sciences CVRS
Study Section:
Myocardial Ischemia and Metabolism MIN

Dr. Richard Schneiderman received his Ph.D. in immunology from The University of Illinois, Chicago, where he studied cellular and molecular mechanisms regulating immunoglobulin A expression and function. He completed postdoctoral training in retroviral biology and gene therapy initially at Genetic Therapy Inc. in Gaithersburg, MD. Dr. Schneiderman then served in the Laboratory of Cell Biology at the NIH National Institute of Mental Health, investigating vector biology, receptor interaction and host restriction. He then moved to Baxter Healthcare Corporation, where he was a Principal Scientist investigating a number of gene and cell therapy approaches for hemophilia and diabetes. Before coming to CSR, Dr. Schneiderman was a Principal Scientist at Boehringer Ingelheim Pharmaceuticals and Acorda Therapeutics investigating therapeutic treatments for cardiovascular diseases including atherosclerosis, heart failure, and hypertension.